Results 121 to 130 of about 65,300 (300)

Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells

open access: yes, 2014
Johannah Sharman, Michael Pennick Shire, Basingstoke, UK Abstract: Lisdexamfetamine dimesylate (LDX) is approved as a once-daily treatment for attention-deficit/hyperactivity disorder in children, adolescents, and adults in some countries.
Sharman J, Pennick M
core  

Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance

open access: yes, 2017
Multidrug resistance (MDR) is a main obstacle in cancer chemotherapy. The MDR mechanisms involve P-glycoprotein (P-gp) overexpression, abnormality of apoptosis-related protein, and altered expression of drug-targeting proteins.
Meng Zhang (154027)   +6 more
core   +1 more source

Prodrugs eller prodruger? [PDF]

open access: yesTidsskrift for Den norske legeforening, 2016
openaire   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

open access: yesBMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo   +9 more
wiley   +1 more source

An all-in-one tetrazine reagent for cysteine-selective labeling and bioorthogonal activable prodrug construction

open access: yesNature Communications
The prodrug design strategy offers a potent solution for improving therapeutic index and expanding drug targets. However, current prodrug activation designs are mainly responsive to endogenous stimuli, resulting in unintended drug release and systemic ...
Xinyu He   +7 more
doaj   +1 more source

Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy

open access: yes, 2018
Jiajiang Xie,1,2,* Zhongxiong Fan,2,* Yang Li,2,* Yinying Zhang,2 Fei Yu,3 Guanghao Su,4 Liya Xie,5 Zhenqing Hou2 1Xiamen Xianyue Hospital, Xiamen, China; 2Research Center of Biomedical Engineering of Xiamen, Key Laboratory of Biomedical Engineering of ...
Zhang YY   +7 more
core  

Ribonuclease-Activated Cancer Prodrug

open access: yes, 2016
Cancer chemotherapeutic agents often have a narrow therapeutic index that challenges the maintenance of a safe and effective dose. Consistent plasma concentrations of a drug can be obtained by using a timed-release prodrug strategy.
Gregory A. Ellis (1283733)   +3 more
core   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

open access: yesBMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma   +9 more
wiley   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

open access: yesBMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao   +4 more
wiley   +1 more source

Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis

open access: yes, 2013
Jamal A Jilani,1 Maha Shomaf,2 Karem H Alzoubi3 1Department of Medicinal Chemistry and Pharmacognosy, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Pathology, Jordan University, Amman, Jordan; 3Department of Clinical Pharmacy,
Jilani JA, Alzoubi KH, Shomaf M
core  

Home - About - Disclaimer - Privacy